Phio Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The discussion highlighted a novel siRNA-based therapy for cutaneous squamous cell carcinoma, showing strong early clinical results and the potential to reduce reliance on surgery. The technology platform is adaptable to other cancers, with upcoming regulatory milestones and a focus on minimizing dilution risk for investors.
-
A novel RNA-based immunotherapy for skin cancer showed strong efficacy and safety in phase I-B trials, with plans to advance to phase II-B/III next year. The company is well-capitalized, focusing on high-value indications and out-licensing non-core assets.
-
A novel RNA-based therapy for skin cancer demonstrated strong efficacy and safety in early trials, with 85% response at the highest dose and no toxicities. The company is preparing for pivotal studies, has a robust IP portfolio, and is exploring partnerships for broader applications.